Can trimethoprim‑sulfamethoxazole (Bactrim) cause neutropenia in a patient who develops fever and a diffuse rash while taking it?

Can Trimethoprim-Sulfamethoxazole Cause Neutropenia?

Yes, trimethoprim-sulfamethoxazole (Bactrim) can definitely cause neutropenia, and this is a well-documented adverse effect that occurs through its antifolate mechanism, particularly affecting patients with folate deficiency or increased folate requirements. 1

Mechanism and Incidence

• Trimethoprim is the primary culprit causing neutropenia through its antifolate action, which inhibits granulopoiesis by blocking dihydrofolate reductase. 2
• The neutropenia is dose-related and reversible with folinic acid therapy or drug discontinuation. 1
• In vitro studies demonstrate that trimethoprim at therapeutic concentrations (8 micrograms/ml) causes a 47% decrease in granulocyte colony formation in folate-deficient conditions, which is completely prevented by folinic acid supplementation. 2

High-Risk Populations

Certain patient groups face substantially elevated risk:

• AIDS/HIV patients: 40-65% of HIV-infected adults experience adverse reactions to TMP-SMX, with neutropenia being a prominent feature. 1, 3
• Patients with folate deficiency: Including elderly, chronic alcoholics, those on anticonvulsants, malabsorption syndromes, and malnourished states. 1
• Patients with pre-existing renal or hepatic dysfunction have increased susceptibility to hematologic toxicity. 1

Clinical Presentation Timeline

• Neutropenia typically appears after 5-10 days of therapy, with a median onset of 7.5 days in AIDS patients. 3, 4
• In one fatal case, severe neutropenia developed after only 5 days of standard-dose therapy. 4
• A healthy adult developed agranulocytosis (ANC 0.0) after completing a 10-day course, demonstrating that toxicity can manifest even after drug completion. 5

Severity Spectrum

The neutropenia can range from mild to life-threatening:

• Mild reversible neutropenia is common, particularly in prophylactic use (occurring in approximately 11.5% of pediatric oncology patients). 6
• Severe agranulocytosis (complete absence of neutrophils) has been documented in otherwise healthy adults. 5
• Fatal outcomes have occurred despite aggressive supportive care including filgrastim, transfusions, and growth factors. 4

Context of Fever and Rash

When a patient develops fever and diffuse rash while taking TMP-SMX, neutropenia is part of a constellation of hypersensitivity reactions:

• The FDA label explicitly warns that patients developing rash, fever, and leukopenia should have therapy immediately discontinued and benefit-risk reassessed. 1
• This triad (rash, fever, neutropenia) is particularly common in AIDS patients treated for Pneumocystis pneumonia, occurring significantly more frequently than in non-AIDS patients. 1, 3
• In one severe case, rechallenge after initial rash/fever/neutropenia resulted in anaphylactoid reaction with pulmonary edema and rhabdomyolysis. 7

Monitoring Requirements

The FDA mandates specific hematologic surveillance:

• Complete blood counts with differential and platelet counts should be performed at initiation and monthly intervals during TMP-SMX therapy. 8, 1
• More frequent monitoring is warranted in high-risk patients (AIDS, folate deficiency, renal impairment). 1

Management Approach

If neutropenia develops:

1. Immediately discontinue TMP-SMX if neutropenia is detected or if the patient develops the triad of rash, fever, and any sign of bone marrow suppression. 1
2. The neutropenia is reversible upon drug discontinuation, typically resolving within 6 days as demonstrated in the agranulocytosis case. 5
3. Folinic acid (leucovorin) can reverse the hematologic effects in cases where folate antagonism is the mechanism. 1
4. Never rechallenge patients who developed severe hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome, or severe neutropenia with rash/fever). 8, 1

Critical Caveat

Do not confuse drug-induced rash with infection-related rash in patients being treated for suspected infections, as this misattribution delays appropriate antimicrobial therapy changes. 9 In the context of fever and diffuse rash developing during TMP-SMX therapy, drug reaction should be the primary consideration, not treatment failure or superinfection.